|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.
100 项与 SLAMF2 x Tubulin 相关的临床结果
100 项与 SLAMF2 x Tubulin 相关的转化医学
0 项与 SLAMF2 x Tubulin 相关的专利(医药)